Absci筹集了6 400万美元,将其AI驱动的药物发现平台推展至2028年。 Absci raised $64 million to boost its AI-driven drug discovery platform through 2028.

Absci公司筹集了6 400万美元的资金,用于在2028年之前推进其AI驱动的药物发现平台。 Absci Corporation has raised $64 million in funding to advance its AI-powered drug discovery platform through 2028. 首都将支持加快治疗发展的努力,利用人工智能预测蛋白质行为,完善药物候选者,并简化临床前研究。 The capital will support efforts to accelerate therapeutic development by using artificial intelligence to predict protein behavior, refine drug candidates, and streamline preclinical research. 该公司旨在设计更加稳定、有效和可制造的蛋白质,有可能减少药物开发的时间和成本。 The company aims to design more stable, effective, and manufacturable proteins, potentially cutting time and costs in drug development. 基金还将扩大计算基础设施,改进AI模型,并加强伙伴关系。 Funds will also expand computational infrastructure, improve AI models, and strengthen partnerships. 这项投资反映出对AI在生物制药创新中的作用的信心日益增强,标志着Absci通过数据驱动方法改变毒品发现使命的关键一步。 The investment reflects growing confidence in AI’s role in biopharmaceutical innovation and marks a key step in Absci’s mission to transform drug discovery through data-driven approaches.